NCT05327803Phase 2, phase 3Terminated

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Study sponsor: AN2 Therapeutics, Inc · ANTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-18Actual
Enrollment · participants177Actual
Source updated2026-06-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview